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Abstract
Introduction: African-American black men race is one of non-modifiable risk factors confirmed for prostate cancer.
Many studies have been done in USA among African- American population to evaluate prostate cancer disparities.
Compared to the USA very few data are available for prostate cancer in Sub-Saharan African countries. The
objective of this study was to describe incident prostate cancer (PC) diagnosis characteristics in Burkina Faso
(West Africa).
Methods: We performed a prospective non randomized patient’s cohort study of new prostate cancer cases
diagnosed by histological analysis of transrectal prostate biopsies in Burkina Faso. Study participants included 166
patients recruited at the urology division of the university hospital of Ouagadougou. Age of the patients, clinical
symptoms, digital rectal examination (DRE) result, serum prostate-specific antigen (PSA) level, histological
characteristics and TNM classification were taking in account in this study.
Results: 166 transrectal prostate biopsies (TRPB) were performed based on high PSA level or abnormal DRE. The
prostate cancer rate on those TRPB was 63, 8 % (n=106). The mean age of the patients was 71, 5 years (52 to 86).
Urinary retention was the first clinical patterns of reference in our institution (55, 7 %, n = 59). Most patients, 56, 6
% (n = 60) had a serum PSA level over than 100 ng/ml. All the patients had adenocarcinoma on histological study
of prostate biopsy cores. The majority of cases (54, 7 % n = 58) had Gleason score equal or higher than 7.
Conclusion: Prostate cancer is diagnosed at later stages in our country. Very high serum PSA level and poorly
differentiated tumors are the two major characteristics of PC at the time of diagnosis.
Introduction
African-American black men race is one of non-modifiable
risk factors confirmed for prostate cancer (PC). Many
studies have been done in USA among African-American
to evaluate prostate cancer disparities in this population.
African-Americans have more advanced stages of PC
at diagnosis and higher mortality rates for PC than whites.
[1-4] There is no scientific proof that PC in African-
Americans has the same characteristics in their ancestry
from Central and West Africa but there is documented evi-
dence in the literature indicating that prostate cancer in
one West African country, Nigeria, is similar to rates found
in the United States [5]. Compared to the USA very few
data are available for prostate cancer in Sub-Saharan
African countries [1,2]. This work aims to contribute by
providing more data about PC in West Africa and to parti-
cipate in the research to reduce prostate cancer disparities
in black men. In Burkina Faso (West Africa) PC epidemiol-
ogy, clinical and pathological characteristics are not well
evaluated. This study is the first to assess PC particularity
at the biggest urology division in the university hospital of
the main city of Burkina Faso: Ouagadougou. The objective
of the study was to describe PC diagnosis characteristics at
the time of diagnosis in our country.
Methods
We performed a prospective non randomized patient’s
cohort study of new PC cases diagnosed in Burkina Faso.
Study participants included 166 patients recruited at the
urology division of the university hospital of Ouagadou-
gou. Our institution receives patients from all over the
country. PC cases were diagnosed at histological analysis
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patients who had abnormal digital rectal examination
(DRE) or high serum prostate-specific antigen (PSA)
level. The recruitment of all patients was made between
January 2009 and June 2010. The variables of interest
included age at diagnosis, the clinical symptoms of refer-
ence in our center for PC, serum PSA level, information
about prostate biopsy (histological type, Gleason score)
and stage of tumor determined according to the TNM
2007 classification. The existence of metastatic PC was
evaluated with clinical exam and thoraco-abdominal and
pelvis computed tomography. Descriptive statistics were
used to summarize these variables in terms of the means,
extremes values, and frequencies.
Results
One hundred and sixty six (166) TRPB were performed
based on high PSA level or abnormal DRE. The prostate
cancer rate on those TRPB was 63, 8 % (n =106). The
mean age of the patients was 71, 5 years (52 to 86). All
patients had abnormal DRE. Figure 1 summarizes the
clinical symptoms at the time of diagnosis. The mean
duration of symptoms prior to presentation was 12.6
months (range: 1 month to 6 years). Urinary retention
was the first clinical patterns of reference in our institu-
tion (55, 7 %, n = 59). Most patients, 56, 6% (n = 60)
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The mean serum PSA level was 537ng/ml (8, 41 to
17850). All the patients had adenocarcinoma on histolo-
gical study of prostate biopsy cores. The majority of
cases (54, 7 % n = 58) had Gleason score equal or
higher than 7 [Figure 3]. Most patients, 73, 6 % (n = 78)
had their primary tumor extended over the prostatic
capsule (T3-T4 stages). Table 1 summarizes the lymph
nodes (N) involvement and metastatic PC (M) according
to primary tumor stage (T).
Discussion
Numerous studies have reported that black men are
diagnosed with prostate cancer at a younger age [3,6]
than white men. Many other studies suggest that there
are no age differences at the time of PC diagnosis [4,7].
In our study the mean age is higher (71, 5). Older age at
the time of diagnosis of PC is commonly reported from
West Africa [8-11]. The majority of patients in this
study (84 %) presented urinary retention or lower urin-
ary tract symptoms (LUTS). According to Ajapé [8] the
severity of urinary symptoms at the time of PC diagnosis
in low resources countries is relevant to late presenta-
tion, ignorance of the population concerning PC symp-
toms, and poverty. Furthermore, the lack of urology
centers (only two public urology centers in Burkina
Faso) can be a reason of late presentation.
Studies have reported that African-American men
diagnosed with prostate cancer have greater PSA levels
than whites [3,9,12,13]. The results of our study
strengthen these reports. However the mean PSA level
in our study is very high. This is relevant to late presen-
tation and the fact that several patients included in this
study were empirically managed for several years for PC
without PSA testing or biopsy in poorly equipped rural
centers. However we cannot exclude a possible “racial-
ethnical” particularity in our country but this must be
assessed by further studies. The relation between high
PSA level in black men, race and genetic is not well
established. Veda [12] finds no evidence in support of
the traditional “race-specific” PSA. He reports that the
PSA has a higher prediction for PC in African-American
Figure 1 Repartition of patients according to Clinical symptoms
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by genetic West African ancestry which needs further
study.
Most PC cases reported in our study were high grade
tumors with poor prognosis (PSA > 20 ng/ml, Gleason
score 7-10, or clinical stage T3-T4). The explanation is late
diagnosis and the lack of PC screening program in our
country. The Gleason score is the most reliable factor in
determining the biological characteristics of prostate can-
cer, tumor stage, and its prognosis. [3,14] Several reports
that black men presented with more poorly differentiated
PC than white. [2,3,15] These results suggest more studies
to evaluate if other factors such as diet, lifestyle, genetics
played a role in high Gleason score reported in black men
prior to late diagnosis and limited access to medical center.
PC screening remains controversial and expose to over
diagnosis and overtreatment. In a recent review, Stavri-
dis [16] concludes that, as we are aware, there is no suf-
ficient evidence to recommend routine population
screening for PC. Nevertheless, clinicians should provide
information about potential benefits and risks of screen-
ing for PC, and the limitations of current evidence for
screening, and make the final decision to screen or not.
However, screening has the potential to reduce PC dis-
parities in African black men. A good PC screening pol-
icy in Burkina Faso can reduce specific mortality by
early diagnosis and raise the population awareness of
PC. Arthur [17] in Ghana promotes screening to
improve early detection, management and prognosis of
PC.
Figure 2 Repartition of patients according to Serum PSA level
Figure 3 Repartition of patients according to Gleason score
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PC is diagnosed at later stages in Burkina Faso. Very high
serum PSA level and poorly differentiated tumors are the
two major characteristics of PC at the time of diagnosis.
Interventions focused on screening, education about the
disease and early detection could substantially improve
these findings. This work suggests more studies are
needed in this country to better access PC epidemiology,
genetics, mortality and survival particularities.
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Table 1 Lymph nodes involvement and metastatics localizations according to primary tumor stage
Primary tumor (T) n/% Lymph node Involvement (N) n/% Metastatic Localization (M) n/%
T1 0/0 0/0 0/0
T2 28/26,4 3/2,8 0/0
T3 40/37,7 12/11,3 12/11,3
T4 38/35,9 30/28,3 32/30,2
Total 106/100 45/42,4 44/41,5
Kabore et al. Infectious Agents and Cancer 2011, 6(Suppl 2):S6
http://www.infectagentscancer.com/content/6/S2/S6
Page 4 of 4